Newly Diagnosed and about to start Tecfidera

Hi Everyone,

I’m newly diagnosed and in my early twenties. Due to the coronavirus, the starting of my treatment was delayed but now I’m about to start my first treatment of Tecfidera. I would love to know everyone’s personal experiences with this drug. I’m very anxious to start because of the side effects I have read about and know that all DMDs come with many unpleasant side effects.

Hi Hannaah

its totally understandable to be anxious about starting a new medication. However it is an absolutely excellent medication to take for MS. I forget the data but pretty sure it is one of the best for MS. In terms of side effects you might get some but then you might not. If you do they could be really minor side effects. For me I was slightly nauseous which got better when I ate before taking it. The nausea quickly passed and now I have no side effects. So please don’t worry it will be fine.

Good luck

Min xx

1 Like

Hi Hannah,

I have been advised to start Tecfidera… but same I feel very anxious about it. You have posted this a few month ago so was wondering if you have started the tablets yet? and if so is there any changes like side effects or anything new?

Many thanks in advance

1 Like

Thank you for your reply! This really helps.

Hi there, been taking it twice a day with food for past 18 months or so. No side effects at all. Good luck.

1 Like

Thank you for your response. I never got notifications for my account and have only seen this now almost 2 years later. Sadly, Tecfidera didn’t work out for me I experienced severe stomach pain and couldn’t take it at all.

Thank you for your response. I never got notifications for my account and have only seen this now almost 2 years later. Sadly, Tecfidera didn’t work out for me I experienced severe stomach pain and couldn’t take it at all. I hope it worked out well for you and would love to know how you personally found it. I was only on it for 2 weeks the stomach pain was too bad. I’m now on Ocrevus since late September 2021.